Temporal/Giant Cell Arteritis Clinical Presentation

  • Author: Tarakad S Ramachandran, MBBS, FRCP(C), FACP; Chief Editor: B Mark Keegan, MD, FRCPC   more...
 
Updated: Feb 3, 2012
 

History

The most commonly reported symptoms are headache (initial symptom in 33%, present in 72%); neck, torso, shoulder, and pelvic girdle pain that is consistent with polymyalgia rheumatica (PMR; initial in 25%, present in 58%); fatigue and malaise (initial in 20%, present in 56%); jaw claudication (initial in 4%, present in 40%); and fever (initial in 11%, present in 35%).

Nonspecific symptoms of cough and sore throat occur in 17% and 11%, respectively, but are rarely the presenting complaints. Amaurosis fugax occurs in 10% overall (initial symptom in 2%), and some degree of permanent visual loss occurs in 8% (initial symptom in 3%).

Less common symptoms, which are almost never the presenting complaint, include limb claudication (8%), transient ischemic attacks (TIAs) or stroke (7%), scintillating scotoma (5%), tongue claudication (4%), diplopia (2%), tongue numbness (2%), and myelopathic symptoms (< 1%).

  • Headache and other craniofacial pain syndromes: The headache of GCA has no pathognomonic features, but typically, and most importantly, the headache is either new in a patient without a history of headaches or of a new type in a patient with a history of chronic headaches.
    • It is usually throbbing, generalized, and continuous. Focal temple pain is present with tenderness on direct palpation.
    • Scalp tenderness may be present with hair combing.
    • Less often, the pain may be predominantly occipital or occipitonuchal.
    • Other craniofacial pain complaints can include jaw claudication, tongue claudication, and facial pain (a rare symptom). Jaw claudication is almost pathognomonic of temporal arteritis, and it is a result of ischemia of the maxillary artery supplying the masseter muscles; it causes pain on speaking or chewing.
    • About 15% of patients report symptoms of carotodynia.
  • PMR: Neck, torso, shoulder, and pelvic girdle pain may occur within the context of this syndrome.
    • PMR occurs in approximately 58%, and is the initial symptom in 25% of patients with GCA.
    • In typical cases of PMR without vasculitic involvement of the peripheral nervous system, electromyographic (EMG) results are normal.
    • Mild EMG abnormalities in an elderly patient that suggest a mild peripheral neuropathy are generally unrelated to PMR or to a vasculitis.
  • The range of neuro-ophthalmologic signs and symptoms in temporal arteritis is broad and includes diverse manifestations of ischemic optic neuropathy, retinal infarction, ophthalmoparesis, pupillary autonomic and anterior ocular segment dysfunction, cortical blindness and associated posterior chiasmal field defects, and complex visual hallucinations.[6] Oculomotor palsy is an uncommon manifestation of temporal arteritis.
  • Amaurosis fugax and visual loss: Amaurosis fugax occurs in 10-12% of patients with GCA, and permanent loss of vision due to AION occurs in 8-23%.
    • Prior to 1960, most series reported that patients with transient loss of vision went on to develop permanent, bilateral loss of vision due to AION.
    • Following monocular onset, the second eye became affected within days.
    • Today, amaurosis fugax often leads to prompt diagnosis and effective corticosteroid therapy.
  • TIAs: Diagnosed entirely on the basis of historical data, TIAs are properly considered in this context.
    • Atherosclerosis, hypertension, and cardiac disease are the most important causes of cerebral infarction in the elderly with or without GCA, but the known propensity of GCA to affect carotid and vertebral arteries should be considered in GCA patients with TIAs and cerebral infarction.
    • Approximately 4% of patients with GCA experience TIA or stroke at some point during their illness, although how many specifically result from GCA is unclear.
    • A greater proportion of TIAs and infarctions occur in the vertebrobasilar territory than the carotid territory in patients with GCA than in the general population.
    • Few clinical features reliably distinguish a vasculitic from an atheromatous cause, although in rare instances, atheroembolic material has been observed funduscopically or angiographically in the setting of active GCA.
    • Vertebrobasilar events sometimes present as acute confusional states or coma as opposed to discrete focal syndromes.
  • Confusion and encephalopathy: Encephalopathy is a rare complication of GCA; however, the differential diagnosis is extensive.
  • Confusion may be due to steroids, either primarily (steroid psychosis) or secondarily from a steroid-induced metabolic derangement, or to systemic or CNS infections (including infections that occur in immunocompromised hosts).
  • Unrelated causes include degenerative dementia, chronic subdural hematoma, sedating medications, and other diseases prevalent in the elderly.
  • Acute encephalopathy may be caused by GCA itself as a result of cerebral infarction. Presumably, cognitive changes reflect thalamic, mesial temporal, and mesencephalic involvement in most cases. CT scan or, preferably, MRI should be done early in these patients.
  • Acute encephalopathy is a poor prognostic sign. Many patients with this complication progress to coma and die.
  • With giant cell arteritis, Cerebrovascular accidents can occur during the course of the giant cell arteritis (3-4%), involve both anterior and posterior circulations (either alone or in combination), and may lead to multi-infarct dementia. Solans-Laqué et al report 7 patients with biopsy-proven giant cell arteritis who presented with stroke or multi-infarct dementia.[7]
  • When recognized and treated promptly with increased dosages of steroids, patients can stabilize and, over time, experience some recovery.
  • Giant cell arteritis may present as an isolated form or a part of systemic disease. Onuma et al described a rare case of giant cell arteritis involving the female genital tract.[8]
  • Adams et al described a very unusual presentation of temporal arteritis and an extremely rare manifestation of scalp necrosis.[9]
  • Goicochea et al present 3 cases of tongue necrosis due to giant cell granulomatous arteritis. Ischemic necrosis of the tongue is unusual but there appears to be an association between its occurrence and high-dose steroid tapering.[10]
Next

Physical

Physical signs parallel symptoms and are dependent on the organ systems that are damaged by vasculitic ischemia.

  • Superficial temporal artery inflammation: Signs are present in 49% of patients, including erythema, pain on palpation, nodularity, thickening, or reduced pulsation on the affected side. Although rare, ischemic necrosis of the scalp and tongue can occur.
  • AION is caused by vasculitis of the posterior ciliary artery.
    • Less commonly, optic neuropathy is entirely retrobulbar. On rare occasions, blindness results from central retinal artery occlusion.
    • Ophthalmoscopy in acute AION may show sludging of blood in retinal arterioles, which can be orthostatically sensitive. Vision loss precedes the funduscopic changes of optic nerve infarction by roughly 36 hours. Acutely, the disc is pale with blurred margins.
    • As AION evolves, the absolute amount of disc elevation tends to be modest ( < 3 diopters in most cases), with infrequent areas of disc hemorrhage. Edema resolves within 10 days or so; within 2-4 weeks, it is replaced by optic atrophy.
    • Residual visual field defects are usually altitudinal.
    • With retrobulbar involvement, optic pallor and atrophy gradually develop without antecedent papillitis.
    • Central retinal artery occlusion causes pallor and edema of the entire retina and optic disc together with a macular cherry-red spot.
    • Visual loss on presentation was associated with disc swelling and a history of hypertension. Risk factors for progressive visual loss included older age, elevated C-reactive protein, and disc swelling.[11] The r ole of individual risk anticipating treatment regimens and strategies involving the visual prognosis in temporal arteritis remains uncertain.
  • Oculomotor impairment: Diplopia occurs in roughly 2-14% of patients with GCA.
    • The oculomotor apparatus can be involved at any level, including the extraocular muscles (EOM), nerves, and brain stem. However, the most common site is the EOM.
    • A characteristic feature of EOM involvement is daily fluctuation of the ocular motility disorder.
    • Horner syndrome is uncommon, judging from a review of several large series; however, ptosis and miosis may occur together, separately, or in conjunction with other oculomotor disturbances.
  • Peripheral nerve and muscle signs: The vasculitis of GCA can affect large peripheral arteries and their branches. When it involves the nutrient arteries of peripheral nerves, mononeuropathies or mononeuritis multiplex may result.
    • The incidence of acute ischemic mononeuropathies in patients with GCA is difficult to estimate but is probably around 2%.
    • Essentially all named peripheral nerves can be involved in ischemic mononeuropathies.
    • Among spinal nerve roots, the fifth cervical has been reported to be susceptible to GCA by several authors.
    • Patients with GCA can also develop mononeuropathies (which occur at common compression sites) unrelated to vasculitis. For example, approximately 5% have carpal tunnel syndrome. Some of these cases may be related to median nerve compression by synovitis related to PMR.
    • Elderly patients frequently have mildly abnormal nerve conduction studies and EMG suggesting a mild peripheral neuropathy, regardless of whether they have GCA. Once again, the relationship of such neuropathies to the systemic inflammatory state in some patients is uncertain. In other patients, antecedent ischemic mononeuropathies may occur and eventually resemble a "diffuse," severe, peripheral neuropathy.
    • GCA does not cause an inflammatory myopathy, although rare examples of localized muscular inflammation are known. PMR may lead falsely to the clinical suspicion of a myopathy. Steroid therapy commonly causes a mild, noninflammatory myopathy ("steroid myopathy").
  • Myelopathy: A few cases of patients developing an acute cervical myelopathy within the context of active GCA have been reported. The vasculitis presumably extends to the anterior spinal artery from the vertebral arteries.
  • Although rare, myelopathic involvement represents a serious complication and may presage a fatal outcome.
  • Prompt treatment with corticosteroids may result in neurologic stabilization and improvement.
  • Arterial bruits: Bruits in GCA reflect the topographic distribution of GCA.
  • Carotid bruits occur in 10-20% of patients with GCA and are frequently bilateral.
  • Among patients with bilateral carotid bruits, 60% also have upper limb bruits or claudication.
  • Approximately 40% of patients with GCA who have carotid bruits experience an ischemic eye or brain complication (amaurosis fugax, TIA, permanent visual loss, or stroke), although permanent deficits (permanent visual loss and stroke) do not occur more often than in patients with GCA who do not have carotid bruits.
  • Altered mental status: Recurrent episodes of acute encephalopathy with progressive cognitive impairment can lead to a chronic dementia in patients with GCA.
  • This may occur as steroid dosage is tapered.
  • Because these patients are elderly, they may be assumed incorrectly to have Alzheimer disease. Instead, they have a multiinfarct dementia due to cervicocephalic arterial involvement by GCA.
  • CT scan and MRI demonstrate multiple areas of infarction, although EEG findings are inconsistent.
  • These patients are typically on steroids, and their ESR may or may not be increased during these disease exacerbations. Higher dosages of steroids will not result in immediate cognitive recovery; however, longitudinal follow-up should show no further deterioration and may show modest improvement.
  • Currently, encephalopathy or dementia is thought to be a rare occurrence, although earlier literature suggested that it was common.
Previous
Next

Causes

The cause of this autoimmune disorder is not known. Although mycoplasma and parvovirus B19 infection have been implicated, it is generally accepted that they are only "innocent bystanders."

Previous
 
 
Contributor Information and Disclosures
Author

Tarakad S Ramachandran, MBBS, FRCP(C), FACP  Professor of Neurology, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Chair, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, FRCP(C), FACP is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners, American College of International Physicians, American College of Managed Care Medicine, American College of Physicians, American Heart Association, American Stroke Association, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, and Royal Society of Medicine

Disclosure: Abbott Labs None None; Teva Marion None None; Boeringer-Ingelheim Honoraria Speaking and teaching

Coauthor(s)

Arun Ramachandran  State University of New York Upstate Medical University

Arun Ramachandran is a member of the following medical societies: American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Jorge E Mendizabal, MD  Consulting Staff, Corpus Christi Neurology

Jorge E Mendizabal, MD is a member of the following medical societies: American Academy of Neurology, American Headache Society, National Stroke Association, and Stroke Council of the American Heart Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Florian P Thomas, MD, MA, PhD, Drmed  Director, Regional MS Center of Excellence, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Director, Neuropathy Association Center of Excellence, Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, St Louis University School of Medicine

Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Paraplegia Society, Consortium of Multiple Sclerosis Centers, and National Multiple Sclerosis Society

Disclosure: Nothing to disclose.

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Chief Editor

B Mark Keegan, MD, FRCPC  Assistant Professor of Neurology, College of Medicine, Mayo Clinic; Master's Faculty, Mayo Graduate School; Consultant, Department of Neurology, Mayo Clinic, Rochester

B Mark Keegan, MD, FRCPC is a member of the following medical societies: American Academy of Neurology, American Medical Association, and Minnesota Medical Association

Disclosure: Novartis Consulting fee Consulting; Bionest Consulting fee Consulting

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Richard J. Caselli, MD to the development and writing of this article.

References
  1. Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A. Are polymyalgia rheumatica and giant cell arteritis the same disease?. Semin Arthritis Rheum. Apr 2004;33(5):294-301. [Medline].

  2. Borchers AT, Gershwin ME. Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. Jan 21 2012;[Medline].

  3. Eberhardt RT, Dhadly M. Giant cell arteritis: diagnosis, management, and cardiovascular implications. Cardiol Rev. Mar-Apr 2007;15(2):55-61. [Medline].

  4. Nordborg C, Larsson K, Aman P, Nordborg E. Expression of the class I interferon-related MxA protein in temporal arteries in polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol. Mar-Apr 2009;38(2):144-8. [Medline].

  5. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation. Jul 12 2005;112(2):264-9. [Medline].

  6. Mehler MF, Rabinowich L. The clinical neuro-ophthalmologic spectrum of temporal arteritis. Am J Med. Dec 1988;85(6):839-44. [Medline].

  7. Solans-Laqué R, Bosch-Gil JA, Molina-Catenario CA, Ortega-Aznar A, Alvarez-Sabin J, Vilardell-Tarres M. Stroke and multi-infarct dementia as presenting symptoms of giant cell arteritis: report of 7 cases and review of the literature. Medicine (Baltimore). Nov 2008;87(6):335-44. [Medline].

  8. Onuma K, Chu CT, Dabbs DJ. Asymptomatic giant-cell (temporal) arteritis involving the bilateral adnexa: case report and literature review. Int J Gynecol Pathol. Jul 2007;26(3):352-5. [Medline].

  9. Adams WB, Becknell CA. Rare manifestation of scalp necrosis in temporal arteritis. Arch Dermatol. Aug 2007;143(8):1079-80. [Medline].

  10. Goicochea M, Correale J, Bonamico L, Dominguez R, Bagg E, Famulari A. Tongue necrosis in temporal arteritis. Headache. Sep 2007;47(8):1213-5. [Medline].

  11. Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry. Nov 2007;78(11):1255-9. [Medline].

  12. Ortiz Z, Tugwell P. Raised ESR in polymyalgia rheumatica no longer a sine qua non?. Lancet. Jul 6 1996;348(9019):4-5. [Medline].

  13. Kermani TA, Warrington KJ. Recent Advances in Diagnostic Strategies for Giant Cell Arteritis. Curr Neurol Neurosci Rep. Dec 29 2011;[Medline].

  14. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. Mar 1997;123(3):285-96. [Medline].

  15. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. Jul 25 2002;347(4):261-71. [Medline].

  16. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. May-Jun 2004;14(3):245-57. [Medline].

  17. Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. Oct 2006;113(10):1842-5. [Medline].

  18. Foroozan R, Danesh-Meyer H, Savino PJ, Gamble G, Mekari-Sabbagh ON, Sergott RC. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology. Jul 2002;109(7):1267-71. [Medline].

  19. Bley TA, Reinhard M, Hauenstein C, Markl M, Warnatz K, Hetzel A. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum. Aug 2008;58(8):2574-8. [Medline].

  20. Reinhard M, Schmidt D, Schumacher M, Hetzel A. Involvement of the vertebral arteries in giant cell arteritis mimicking vertebral dissection. J Neurol. Aug 2003;250(8):1006-9. [Medline].

  21. Ghinoi A, Pipitone N, Nicolini A, Boiardi L, Silingardi M, Germanò G, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford). Dec 16 2011;[Medline].

  22. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol. Jan 2005;17(1):9-15. [Medline].

  23. Calabrese LH. Clinical management issues in vasculitis. Angiographically defined angiitis of the central nervous system: diagnostic and therapeutic dilemmas. Clin Exp Rheumatol. Nov-Dec 2003;21(6 Suppl 32):S127-30. [Medline].

  24. Warrington KJ, Matteson EL. Management guidelines and outcome measures in giant cell arteritis (GCA). Clin Exp Rheumatol. Nov-Dec 2007;25(6 Suppl 47):137-41. [Medline].

  25. Salvarani C, Giannini C, Miller DV, Hunder G. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum. Dec 15 2006;55(6):985-9. [Medline].

  26. Lenton J, Donnelly R, Nash JR. Does temporal artery biopsy influence the management of temporal arteritis?. QJM. Jan 2006;99(1):33-6. [Medline].

  27. Armstrong AT, Tyler WB, Wood GC, Harrington TM. Clinical importance of the presence of giant cells in temporal arteritis. J Clin Pathol. May 2008;61(5):669-71. [Medline].

  28. Alberts MS, Mosen DM. Diagnosing temporal arteritis: duplex vs. biopsy. QJM. Dec 2007;100(12):785-9. [Medline].

  29. Pountain G, Hazleman B. ABC of rheumatology. Polymyalgia rheumatica and giant cell arteritis. BMJ. Apr 22 1995;310(6986):1057-9. [Medline].

  30. Scheurer RA, Harrison AR, Lee MS. Treatment of vision loss in giant cell arteritis. Curr Treat Options Neurol. Feb 2012;14(1):84-92. [Medline].

  31. Bley TA, Wieben O, Leupold J. Images in cardiovascular medicine. Magnetic resonance imaging findings in temporal arteritis. Circulation. Apr 26 2005;111(16):e260. [Medline].

  32. Calamia KT, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis. 1980;6:389-415.

  33. Caselli RJ. Giant cell (temporal) arteritis: a treatable cause of multi-infarct dementia. Neurology. May 1990;40(5):753-5. [Medline].

  34. Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology. May 1988;38(5):685-9. [Medline].

  35. Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North Am. Nov 1993;19(4):941-53. [Medline].

  36. Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. Mar 1988;38(3):352-9. [Medline].

  37. Fox GN. Giant cell arteritis. CMAJ. Dec 6 2005;173(12):1490; author reply 1490. [Medline].

  38. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore). Sep 2005;84(5):277-90. [Medline].

  39. Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Arthritis Rheum. Dec 15 2002;47(6):662-9. [Medline].

  40. Hollenhorst RW, Brown JR, Wagener HP, Shick RM. Neurologic aspects of temporal arteritis. Neurology. May 1960;10:490-8. [Medline].

  41. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. Feb 1978;88(2):162-7. [Medline].

  42. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med. Dec 1975;83(6):806-12. [Medline].

  43. Meyers AD, Said S. Temporal artery biopsy: concise guidelines for otolaryngologists. Laryngoscope. Nov 2004;114(11):2056-9. [Medline].

  44. Narváez J, Narváez JA, Nolla JM, Sirvent E, Reina D, Valverde J. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxford). Apr 2005;44(4):479-83. [Medline].

  45. Ostberg G. Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand Suppl. 1972;533:135-59. [Medline].

  46. Polak P, Pokorny V, Stvrtina S, et al. Temporal arteritis presenting with paresis of the oculomotor nerve, and polymyalgia rheumatica, despite a low erythrocyte sedimentation rate. J Clin Rheumatol. Aug 2005;11(4):242-4. [Medline].

  47. Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol. Aug 31 2000;75 Suppl 1:S9-S15; discussion S17-9. [Medline].

  48. Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathologicalstudy to show the pattern of arterial involvement. Arch Neurol. Nov 1972;27(5):378-91. [Medline].

Previous
Next
 
Hematoxylin- and eosin-stained superficial temporal artery biopsy specimen, cross section. The hallmark histologic features of GCA shown here include intimal thickening with luminal stenosis, mononuclear inflammatory cell infiltrate with media invasion and necrosis, and giant cell formation in the media.
Lumbar angiogram showing stenosis and occlusion of femoral artery branches due to vasculitis.
Hematoxylin- and eosin-stained femoral artery branch, cross section, taken from a lower limb amputation specimen. Mononuclear cell invasion and necrosis in the media of this large artery can be observed. Extensive lower limb vasculitis from GCA resulted in ischemic necrosis of the lower limb, necessitating amputation.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.